熱門資訊> 正文
CRISPR Therapeutics股价因3.5亿美元可转换债券发行而下跌
2026-03-10 19:07
- CRISPR Therapeutics (CRSP) plans to offer $350M aggregate principal amount of its convertible senior notes due 2031 in a private offering.
- The company also expects to grant the initial purchasers a 13-day option to purchase up to an additional $52.5M aggregate principal amount of the notes.
- The notes will accrue interest payable semiannually and will mature on March 1, 2031, unless earlier converted, redeemed, or repurchased.
- The biopharmaceutical company plans to use the net proceeds from the offering for general corporate purposes.
- CRSP shares fell -6.5% premarket to $54.94.
More on CRISPR Therapeutics
- Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take
- Crispr Therapeutics: Very High Risk, But Even Higher Potential Reward
- CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
- Key deals this week: KORE, TopBuild, Equinix, PayPal and more
- Crispr Therapeutics gains amid takeover speculation
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。